{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-007835","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.944477+00:00","generated_at":"2026-06-25T23:36:30.850103+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CytomX Q1 2022 revenue $17.1M; cash $263M; pipeline data expected H2 2022","bullets":["Cash, equivalents and investments $263M at March 31, 2022, down from $305M at Dec 31, 2021.","Total revenue $17.1M for Q1 2022, up from $16.0M in Q1 2021, primarily from AbbVie collaboration.","R&D expenses $30.6M (up $8.2M YoY); G&A $10.5M (up $1.3M YoY); operating loss implied.","Phase 2 praluzatamab ravtansine: Arm A enrollment complete; initial data for Arms A & B in H2 2022.","CX-2029 completed enrollment in squamous NSCLC cohort; data update expected in H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-007835","json":"https://secwatch.observer/filing/0000950170-22-007835.json","markdown":"https://secwatch.observer/filing/0000950170-22-007835.md","text":"https://secwatch.observer/filing/0000950170-22-007835.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000095017022007835/0000950170-22-007835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000095017022007835/ctmx-20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:36:30.850103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}